FDA Approves Test to Identify Gastroesophageal Cancer Patients Eligible for Jazz Pharmaceuticals' Ziihera
MT Newswires Live
3 hours ago
The US Food and Drug Administration has approved usage of Roche's diagnostics tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma patients who may be eligible for treatment with Jazz Pharmaceuticals' (JAZZ) Ziihera, Roche said Wednesday.
Roche further said that two Ziihera-containing regimens are now FDA approved for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive GEA.
Shares of Jazz Pharmaceuticals were down 4.3% in Wednesday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.